Humana Inc. Reports Fourth Quarter 2025 Financial Results and Provides Full Year 2026 Guidance
1. Overview of Financial Performance
In a press release dated February 11, 2026, Humana Inc. (NYSE: HUM) announced its financial results for the fourth quarter of 2025 (4Q25) and the full year 2025 (FY 2025). The company experienced a significant net loss per share for the fourth quarter, alongside a decline in consolidated pretax income compared to the same period in 2024.
Key Financial Highlights
For 4Q25, Humana reported a consolidated pretax loss of $1,011 million, compared to a loss of $862 million in 4Q24. Adjusted (non-GAAP) results showed a loss of $596 million for the quarter, a notable increase from the loss of $296 million in the prior year quarter.
In terms of earnings, the GAAP net loss per share stood at ($6.61) for 4Q25, compared to ($5.76) in 4Q24. Conversely, for the full year 2025, Humana reported a GAAP EPS of $9.84, slightly down from $9.98 in FY 2024.
Significant Adjustments Impacting Results
The financial results were heavily influenced by several non-GAAP adjustments:
- Impairment Charges: Humana recorded impairment charges of $221 million in 4Q25, contributing significantly to the overall loss.
- Value Creation Initiatives: The company engaged in various initiatives, resulting in charges of $129 million in the fourth quarter.
- Exit of Employer Group Commercial Medical Products Business: This exited segment created a positive impact on the previous year's results, contrasting with the current quarter.
2. Full Year 2026 Financial Guidance
Humana also provided its earnings guidance for FY 2026, projecting a GAAP EPS of at least $8.89 and an adjusted EPS of at least $9.00. This guidance reflects an anticipated year-over-year decline, primarily attributed to headwinds associated with the Star Ratings for Bonus Year 2026.
Earnings Guidance Breakdown
| Earnings Measure | FY 2026 Guidance | FY 2025 Actual |
|---|---|---|
| GAAP EPS | at least $8.89 | $9.84 |
| Adjusted EPS | at least $9.00 | $17.14 |
The guidance underscores the company's expectation of challenges ahead, particularly in light of the Star Ratings, which are crucial as they impact quality bonus payments from the Centers for Medicare & Medicaid Services (CMS).
3. Management Commentary
Jim Rechtin, President and CEO of Humana, expressed cautious optimism regarding the company’s operational strategies and financial trajectory. "We were pleased with our solid financial performance and operational progress in 2025," Rechtin stated, highlighting the company's focus on a consumer-centric approach and growth in individual Medicare Advantage membership for 2026.
4. Conclusion
Humana's financial results for the fourth quarter of 2025 indicate a challenging environment as the company navigates through losses and prepares for future hurdles. The projected guidance for 2026 reflects ongoing strategic initiatives aimed at enhancing operational efficiencies while managing external pressures. As Humana continues to adapt to the evolving healthcare landscape, stakeholders will be keenly observing how these factors influence the company's performance in the upcoming year.
